Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development

Advocacy for better drugs and access to treatment has boosted the interest in drug discovery and development for Chagas disease, a chronic infection caused by the genetically heterogeneous parasite, Trypanosoma cruzi. In this work new in vitro assays were used to gain a better understanding of the a...

Descripción completa

Detalles Bibliográficos
Autores principales: Moraes, Carolina B., Giardini, Miriam A., Kim, Hwayoung, Franco, Caio H., Araujo-Junior, Adalberto M., Schenkman, Sergio, Chatelain, Eric, Freitas-Junior, Lucio H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4004771/
https://www.ncbi.nlm.nih.gov/pubmed/24736467
http://dx.doi.org/10.1038/srep04703

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4004771/
https://www.ncbi.nlm.nih.gov/pubmed/24736467
http://dx.doi.org/10.1038/srep04703

Ejemplares similares